-
Försiktig optimism för life science
Trots det tuffa ekonomiska läget var de flesta investerarna som presenterade sig på Sweden Bios Life Science Investment Day i måndags försiktigt positiva.
-
Biopharma vinner pris
- En enastående affärsmodell har resulterat i starka bedrifter, säger Shrikanth S, arbetsledare för affärer och finans på Frost & Sullivan.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Orion cuts 205 jobs
The Finnish company Orion has completed its statutory negotiations. By this, personnel will be reduced by about 205 in Finland.
-
Academy for a new turn at work
Are you qualified within life science, but unemployed? Here is your chance for a new career, in high demand.
-
Bring talent to those in need
Ho ho ho, Christmas time is here again. So get busy decking the halls, perhaps not with assorted greenery, but with something of a more lasting value.
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING